However, PFS difference according to treatment-line (≤ 3 or > 3), age (< 40 or ≥ 40) or sensitivity to previous platinum compounds was failed to reach statistical significance (Table 3 ).
← all excerpts
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.
1
—
—